Published • loading... • Updated
Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
The plant will boost output of Foundayo and other medicines as Lilly says the pill now accounts for one in three new oral weight-loss starts.
- On Monday, Eli Lilly CEO Dave Ricks broke ground on a $6.5 billion manufacturing facility at Generation Park in Houston, Texas, expected to be operational by 2030.
- Ricks told CNBC that one-third of new GLP-1 pill patients are taking Foundayo, driving Lilly's production ramp to compete against rival Novo in the obesity-treatment market.
- Since 2020, Lilly has committed more than $50 billion to expand its manufacturing network, positioning itself to meet growing demand for obesity and diabetes treatments.
- Medicare's landmark obesity drug coverage, which began in July, is expected to expand access to Foundayo and Zepbound; Foundayo booked $98 million in second-quarter sales.
- Lilly committed an additional $27 billion in February 2025 to build four new facilities, including the Houston site, partly to build goodwill with President Donald Trump.
Insights by Ground AI
6 Articles
6 Articles
Eli Lilly breaks ground on $6.5B pharmaceutical factory in Houston
Leading pharmaceutical company Eli Lilly broke ground today, Sept. 21, on its $6.5 billion manufacturing site at Houston's Generation Park. The 236-acre, state-of-the art factory is expected to come online in 2030 and will manufacture Foundayo, the company's first synthetic oral GLP-1 medication, currently under regulatory review, as well as other advanced therapeutics. "We are thrilled to break ground on our latest ‘medicines made in America’ s…
According to CNBC, CEO of Eli Lilly says that one-third of new GLP-1 patients use the Foundayo; company builds US$6.5 bi in Houston
Coverage Details
Total News Sources6
Leaning Left1Leaning Right1Center1Last UpdatedBias Distribution34% Left, 33% Center, 33% Right
Bias Distribution
- 34% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
34% Left
L 34%
C 33%
R 33%
Factuality
To view factuality data please Upgrade to Premium
